Merck & Co., Inc. (MRK) Stock Forecast & Price Target

Merck & Co., Inc.
Bear Case

Investors should be bearish about investing in Merck for these reasons:

• Merck reported a loss of $0.13 per share in Q2 2026, which, while better than the expected loss of $0.26, still indicates that the company is not currently profitable on a per-share basis for that quarter.
• The company has a high price-to-earnings ratio of 115.86, which may indicate that the stock is overvalued relative to its current earnings, especially given the recent losses reported in the last two quarters.
• Merck faces the risk of Keytruda losing exclusivity in 2028, which could significantly impact revenue unless the company successfully launches new drugs to offset this loss, a challenge that is still ongoing.
• Insiders have sold 228,238 shares worth approximately $30 million in the last 90 days, including significant sales by EVPs David Williams and David Maraldo, which may signal a lack of confidence from company leadership.
• Wall Street Zen recently downgraded Merck from a Buy to a Hold rating, reflecting a more cautious outlook on the stock's near-term performance compared to other analysts who maintain higher targets.